BNT162b3 Uses, Dosage, Side Effects and more

The BNT162b3 vaccine is the latest addition to BioNTech and partner Pfizer’s mRNA COVID-19 vaccine program. Similar to BNT162b2, BNT162b3 uses a nucleoside-modified RNA (modRNA) technology. Pfizer and BioNTech deemed this compound as promising in preclinical trials and have decided to initiate further testing of it. As such, BNT162b3 has entered a phase I/II study in early September 2020 (NCT04537949).

Trade Name BNT162b3
Generic BNT162b3
Type
Groups Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated: January 7, 2025 at 1:49 am

Innovators Monograph


*** Taking medicines without doctor's advice can cause long-term problems.
Share